Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (7509)	12/15/2002 7:45:41 PM
From: Icebrg	Respond to of 52153

On second thought it should of course also be said that the IMCL and ELN stories taught investors that it was possible that biotech companies may very well deflate due to factors that didn't have much to do with the drugs under development. Adding to the typical biotech risks. And as most biotechs don't see much revenue coming their way this makes them even more risky than normal corporate disasters. And in the case of Elan not even their revenues and positive cash-flow insulated them when (unfounded) doubts emerged regarding their viability.